Nir Barzilai on keeping longevity research relevant to humans, developing gerotherapeutics and making the best decisions.

Last month, USIsraeli startup SIRTLab announced the appointment of leading geroscience researcher Dr Nir Barzilai as its Chief Medical Adviser, adding additional longevity kudos to a company founded by Boaz Misholi and Professor Haim Cohen, a world leader in research of SIRT6, who has seen over $40 million invested in his research.

SIRTLab has the development of therapeutics that boost levels of SIRT6 in its sights, and given that SIRT6 has been shown to protect against agingassociated pathologies, including metabolic disease and cancer, and to promote longevity [1], it is no wonder that SIRTLab styles itself as “focused on longevity”. The company includes liver disease, frailty, metabolic syndrome, neurodegeneration and inflammatory conditions among its targets, and we grabbed some time with Nir Barzilai to find out more about his hopes for SIRT6 and how SIRTLab is moving forward.

Visit Longevity.Technology https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter https://bit.ly/3AMIXuq
Facebook https://bit.ly/3z8H1v5
Instagram https://bit.ly/3IDvVRX
Linkedin https://bit.ly/3yIfDmf